We conducted a retrospec tive study of 50 ears in 48 pati ents in whom we p erform ed revision tympan omastoid surgery for chronic otitis media. We f ound that the most common probable causes fo r the fa ilure of previous surgery were incomplete lowering of the f acial ridge (94% of cases ), persistent sinodural-angle air-cell disease (92%), persistent tegmental air-cell disease (88% ), recurrent or persistent cholesteatoma (66%), persistent mastoid-tip air-cell disease (62%), a small meatus (60%), and persistent liypotympanic air-cell disease (56%). After a mean postoperative fo llow-up of 26 months, we fo und no app reciabl e difference in success rates between patients who had undergone only one previous surgery (93%) and those who had unde rgone more than one p revious surgery (95%) prior to referra l to our center. Follow-up hearing data revealed a statistically significant improvement in air and bone conduction and a nonsignificant reduction in the air-b one gap. We conclude that revision mastoid surgery fo llowing multiple earlier surgical f ailu res does not carry an apprec iably higher risk of failure than does initial revision surgery. Moreover, there appears to have been no change in the causes offa ilure fo llowing mastoid surgery over the past 3 decades.
Introduction
The goals of surg ery for otitis med ia are universal and have been clearly articul ated in the past.' The mand ates for the surgeon include remo val of disease (e.g., infection and cholesteatoma) in the middl e ear and in the mastoid cavity as well as recon struct ion of the area in a manner designed to minimi ze the risk of recur rent disease. It is also desirable to maximize hearin g postop erati vely and to avoid injury to important neuro vascul ar struc tures .
Th e literatur e is replete with report s on the merit s of the two major surgic al procedures that address these problem s: the canal-w all-down (open-cavity) techniques and the canal-wa ll-up (closed-cav ity) techniques, with or without seco nd-look surgery. !" Wh at is sometimes overlooked in discussion s of the various surg ical approaches is the significant rate of failure or recidivism .' Failure might be the res ult of recurrent or persistent cholesteatoma or persisten t infection and suppuration followi ng surge ry for chroni c otitis media with or without cholestearoma. ' The otologic literature contain s a variety of reports describing the incidence of postoperati ve infect ion or drainage in the ea r follow ing mastoidect om y.1-4 Th e success of tymp anomastoid surgery, the refore, has been defined as the atta inme nt of a dry ear postoperatively. Various authors have reported success rates in the range of 70 to 95%.4 A numb er of articles have identified a subset of surg ical factors that serve as hallm arks of a classic "problem ca vity," or disch argin g mastoid bowl .>" Th e problem cavity is likely to ex hibit a numb er of findin gs that are belie ved to be responsible for failure." These findin gs include a small meatu s, a high faci al ridge, a persistent bony canal wall, a partially rem oved attic wall; a deep mastoid cavity, and a failure of a drum graft attr ibutable to disea sed muc osa and/or active muc opurulent drain age."
In 1974 , Brandow delineated four major factors that he believed are responsible for continued cavity suppuration.? The se factors are (I ) a failur e to completely eradicate the origin al disease, (2) the inability of the cavi ty to cleanse itself, resulting in an acc umulation of excessive debris, (3) persistence of an open eustachian tube, resulting in exposure of the middle ear mucosa, and (4) infection of the skin that lines the mastoid cavity.
In 1978 , Chee sman analyzed the ca uses of surgica l failur e in 141 patient s with chron ic otitis med ia who later req uired revision surgery ."Of the init ial failed operations, 75% were canal-wa ll-dow n procedures. Cheesm that the four leading causes of failure and the impetus behind revis ion surgery were (I) an inadeq uate cartilaginous meatopl asty, (2) a high facial ridge , (3) inadequate management of air-cell disea se, and (4) a failure to exteriorize all cholesteatoma . In 1985, Nadol reviewed the opera tive findings in 66 patients who underwent revision masto id surgery and found recurrent cholesteatoma in 45% of them .I He then reviewed the anatomic location of persistent granulation tissue and found that 4 1% of cases harb ored granulation tissue in tegment al air cells and 38% demonstrated involvement of sinodural-angle air cells. Of those patient s who had undergone previous canal-wa ll-down surgery, 34% had a high facial ridge. Nadol reported that revision surgery was successful in 85% of patients who had previously undergone one to three prim ary mastoid procedures.
For our study, we analyzed a consec utive series of patients who had been refe rred to us for revis ion surge ry after prev ious mastoid surge ry had failed. Our goa ls were to asce rtain the likely causes of the previo us failures and to identify the sites of unexenterated air cells in the tympanomastoid cavity. We also compared our findings with those of simi lar studies conducted duri ng the 1970s and 1980s to test the hypothesis that the ca uses of failure have not changed over the past 3 decades. Mos t important , we sought to determ ine if there was any difference in surgica l outcomes (i.e., dry ear vs drainin g ear) between patients who underwent revision surgery for the first time and those who had undergone mastoid surgery afte r one or more failed revision attempts. Finally, we attemp ted to identify the overall effec ts that successful revision mastoid surgery had on hearing and to illustrate the variety of chall enging issues that face the surgeo n who perform s revision mastoid surgery.
Patients and methods
We retrospectively reviewed the outcomes of 48 consec utive patients who had been referred to our institution for revision mastoid ectomy. We had performed 50 revisions (46 unilateral and two bilatera l) in the 48 patients-30 males and 18 females, aged 7 to 7 1 year s (mean: 39.2)over a 5-year per iod fro m 1995 thro ugh 1999. The 50 ears had undergone a total of86 previous surgeries (range: I to 5; mean: 1.7). T went y ears had undergone more than one prev ious surgery.
We tabulated data on the location of pers iste nt air-ce ll disease, the prese nce or absence of cholestea toma, and the significant mechanical factors that co ntributed to recurrent symptoms. We also analyzed the results of all ava ilable pre-and postoperative hearing eval uations.
One of the authors (C.A. M.) performed all of the revision proce dures described in this study. Patients were treated with one of three revision techn iques: (I ) tyrnpa-720 Figur e 1. Photograph shows the mastoid bowl during revision surgery prior to tympanoplasty. The fa cial ridge has been 1011'ered to the level of the nerve (black arrow head). The stapes (whit e arrowh ead) has been prepared f or total drum replacement (type 3 tympanoplasty). Canaloplasty has resulted in thinned bone at the temporomandibular joint anteriorl y and at the tegmen tympani supe riorly (double arrowheads). nom astoid obliteration, (2) a cana l-wa ll-up proce dure, or (3) a canal-wa ll-down procedure. The latter inclu ded (I) remova l of all air cells at the level of the tegmen, sinodura l angle, and masto id tip, (2) canaloplasty, including removal of tegment al air cells to the level of the tegmen tymp ani and anteriorly to the temporo mandibular joint, and (3) lowerin g oft he facial ridge to the level of the facia l nerve. Care was taken to leave a thin shell of bone over the facial nerve. The facial ridge was lowered inferiorly at the level of the digastric ridge to allow for unencumbered communication between the mastoid bowl and the meatus (fig ure 1). Formal meatoplasty, including removal of conchal cartilage, was also perform ed . Tymp anoplasty (type 3 or4) and total dru m replacement (with temporalis fasc ia) was followe d by split-thickness ski n grafting. The grafting proce dure included oblitera tion of the mastoid cavity with muscle pedicle flaps or, in some cases , bone pate. Type I tympanoplasty was performed in canal-wallup proced ures. Facial nerve function was monitored, and prop hylactic antibiotics were routinely administere d to all patients.
We studied the postoperative cour se following all 50 procedu res up until the time that a clea n and dry ear was achieved . Postoperative audiologic follow -up data were avai lable on 39 of the 50 ears . Outcomes were assessed by co mparing pure-tone averages (500 to 2,000 Hz and 500 to 4,000 Hz) and indiv idual pure tones (250 to 8,000 Hz) before and afterrev ision surger y.The two-t ailed Student' s t test was used for stat istical analysis.
Among the 11 pati ent s (all of whom unde rwent unilat-Happily, Cinderella IS In stable condition .
-:. . . Table 1 . Severe complications of chronic otitis media following previous surgery era l procedures) for whom audiologic follow-up data were not avai lable, three patients had undergone tympanom astoid ob litera tio n (two of who m had a profound sensor ine ura l hea ring loss as a resul t of previous surgery), four were affected with severe develop mental de lay and therefore evaluat ion of their behavioral thresholds was not poss ible, two were surgical fai lures who later wen t on to further revision surgery, and two were lost to follow-up prior to formal postoperati ve audio logy.
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Results
The length of the cli nica l and audiolog ic fo llow -up ranged fro m 1.5 to 49 mo nths (mean : 26) . A successful outcome was defi ned as the attai nme nt of a clean, dry, we llepithelialized cavity with no per sistent or rec urren t cholesteatom a, drai nage, or gran ulation tiss ue . Overall, 47 of the 50 revision su rgeries (94 %) met these cr iteria for success. T here was no appreciable difference in success rates between those who had undergone on ly one previous surgery and those who had und ergone more than one. Of the 30 ears tha t had undergone on ly one previous surgery, success was achieved in 28 (93 %) . Among the 20 ears th at underwent more than one previous surgery, 19 (95 %) were treated successfully .
Types ofrevision surgery. Du ring previous surgery, 32
of the 50 ears (64 %) had been treated with a canal-walldow n procedure and 18 (36 %) with a canal-wall-up procedure . Duri ng rev ision surgery, 42 ears (84 %) were trea ted wit h a canal-wall-down proced ure, five (10 %) with a canal-wall-up procedure, and three (6%) with a A canal -wa ll-down procedure followed by tympanomastoid obl iteration w ith abdominal fat. At our initial eva luatio n, 48 of the 50 ea rs exhibited otorrhea (two of whic h requ ired urgent ca re) and the othe r two were marked by severe debris accum ulation . In addition, we also noted e ight cases of severe co mplicat ions of chro nic otit is med ia following previou s surgery (tab le I ).
Intraoperative findings. During previous surgery, 48
of the 50 ears (96 %) exhibited cholesteatoma; during revision surgery, 33 (66 %) had rec urrent or persisten t cholesteatoma. Intraoperative findings of concern inclu ded nine instances of fac ial nerve de hiscence ( 18%) , one case of horizontal sem icircular ca na l fistula (recurrent cho lestea toma) (2 %), and 18 case s of tegmental dural de hiscence (36 %) , two of whic h req uired co ncomitant middle fossa craniotomy and dura l repair with a bone graft (figure 2). • The most co mmonly reported ad verse events w ith Allegra 6 0 mg bid and placebo in seasona l allergic rhinitis patients 12 and olde r are vira l infection (cold , flu) (2 .5% vs 1.5 %), nausea (1 .6 % vs 1.5 %), and dysmenorrhea (1.5% vs 0 .3%) Please see brief summary of prescrib ing information on ad jacent page. Table 2listsadverse ezperiences inpatientsaged6to11years01 agewhichwere reportedbygreater than 2%01 patientstreated\' nl hfexolenadine hydrochlonde tablets at adose of30mg twice dailyinplacebo-controlled seasonal all er gic rhinilisstudies inIheUnitedStates and canada thatwere morecommonwi thlexolenadine hydrochlonde than placebo, Inrat fertilitystudies, dose-related reduct ionsinimplantsandincreasesinpostlmplantaten losseswereobservedat an oraldose 01 150 mgJ1<g oftertenacme(whichled tolexofenadine hydrochlondeexposuresthat werea pp rox i m a te~3 times theexposure 01the maximum recommended da i~oral dose offexol enadine hydr ochloride inadults).
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TeratogenicEffect s: Category C. There wasnoevidence ofteratogenicityinratsor rabbitsatoral doses ofterfenadineup to300mgJ1<g (whichledtolexolen adine exposures that were approximately 4and 31times, res p ect i v e~, the exposure from themaximum recommended d a i~oral dose offexolenadine inaduits), Ther earenoadequateand well controlledstudies inpregnant women, fexolenadineshouldbeused dur ing pregnancy onl yil the potential benelil jus tifies the potential risktoIheletus.
Nont eratogenic Elfects. Dose-related decreases inpup wei ght gainandsurvival wereobserved inratsexposed toan
oral dose 01 15 0mg,1<g 01 tertenadiae (approximately 3 times the maximum recommended daily oral dose 01Iexot enadine hydrochloride,"aduits based oncompar ison01lexol enadi ne hydrochlorideAUCs), Nur si ng Mothers T~e r e are no adeQualeandwell -controlledstudiesinwomenduring lactat ion. Becausemanydrugs are excreted inhuman milk, cautionshould be exercised when fexofenadine hydrochlor ideisadmin isteredtoanursing woman. PedialricUse The recommendeddose inpatients61011years 01 age isbasedon cross-study compar ison01thepharmacokinetics01 ALLEGRA inadultsand pediatricpatientsand onthe saletyprofile ollexolenadine hydrochloride inboth adult andpediat ricpatients atdoses equal toor higherthan therecommendeddoses. Thesalety 01 ALLEGRA tablets at adose 0130mg h'lice daily has beendemonstratedin438pedatricpatients6to11 years 01age infwo placebo-contr olled 2-Vleekseasonal allergic rhinitistrials. Thesalety 01 ALLEGRAforthe treatment01 chronicidiopalhicurticari ainpatients6to 11 years 01ageisbasedoncross-study compariso n01 the phar macokinetics01 ALLEGRA inad ull andpedlairic patentsand onthesal e~prolile ol lexolenadine inbothadult andpediatric patients at doses equal toor higherthantherecommended dose. Theeneenveness 01ALLEGRA lor the treatment 01seasonal allergic rhinitisinpatients 6to 11year s01age was demonstratedinone trial ( n~41 1) inwhichALLEGRA tablets 30mg!lVice daily significantly reduced total symptom scores compared toplacebo"along.with extrapolafionof demons trated el licacy inpat ients ages 12yearsandabove, and thepnarmacokln e t lccom~arl So ns '" adults and chil dren, Theenectveness01ALLEGRA lor the treatment 01 chronic idiopathic urncana In parents6to11year s 01age IS based onan extrapolation01thedemonstrated effi cacy 01 ALLEGRA inadut ts wi ththisconditi onand thelikel ihood that the disease course, pathophysiology and the drug'seffect are subst ant ially similarin children 10that 01 adult patients, Thesafetyand eflectiveness of ALLEGRA inpediatr ic patientsunder6years01 age havenotbeen established.
Clinical,st udies 01 ALLEGRA tabletsand capsules didnot indudesufficient numbers 01sub jecfsaged 65yearsand over to dete r~mne \.'/hether thiSpopulati on responds differentl yfromyoungerpat ients. Otherreportedclinical experience hasnot identi fied dIfferencesinresponsesbetween thegeri at ric and youngerpatients. Thisdrug isknowntobe substantiall yexcret · ed bythe ki dney, andthe nsk 01t o~c react ionstothisdrugmay begreaterinpatientswi thimpai redrenal lunetian, Because el derlypatientsare more l i ke~tohavede creased renal lunetion, care shoul dbe taken indose selection , andmay beuseful tomonitorrenal lunetiOn. (See CLINICAL PHARMACOLOGY) . ADVERSEREACJIONS Seasonal Allergic Rhinilis Adults. Inpla cebo-controlled seasonal allergicrhinitisclinical tri alsinpatients 12yearsofage andolder, which included 2461patientsreceivi ngtexolenadine hydrochloride capsules atdoses of20mg to240mgh', i ce d a l~. adverseeventswer e similar infexof enadine hydrochloride andplacebo-treatedpatients. All adverseevent sthat werereported bygreaterthan 1% ofpatientswhoreceivedtherecommendedda i~dose otlexol enadine hydrochlori de(60mgcapsules~: nce d a i~) , and that weremorecommon\' nth lexolenadinehydrochloride than placebo, are list ed inTableI, Inaplacebo-eontrolled dinical st udy inthe United States,,' ;hichincluded570patientsaged12yearsand older receivi ng fexol enadlne hydrochlonde tabletsatdoses 01120or18 0mgonce da i~. adverse e'lentsweresimiiarinfexolenadine h y~ro C h l o ri de and.p l acebo -t re~l e d patients. T~b l e 1alsolistsadverse experiences that\' :ere reportedby gr eaterthan2%of patientstrealed W ithfexolenadlne hydrochlOridetablets at doses 0118 0mgonce dailyandthaiweremore common"nth lexolenadine hydrochlondethanplacebo, Theincidenceof adverse events.inclu di ngdrowsiness.\'lasnot dose'relatedand\'las similaracross subgroups defi ned by age, gender, andrace. .
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INDICATIONS AND USAGE Seasonal All ergicRhinilis ALLEGRA isindicaled lor thereliel 01symptomsassociated \'nthseasonal allergicrhinitisinadultsandc!Jildren 6years01 age and older . Symptoms treated e f f e<: t i ve~were sneezing.rhinorrhea, itchynosei palatellhroaLitchyMat erylredeyes. ChronicIdioDathicUrticaria ALLEGRA isindicated fortreaimentof uncomplicated skin manifestations ofchronicidi opathi curticaria inad ultsandchildren 6years 01ageandolder. it s i g n i fi ca n t~re ducespruritusand thenumber01wheals, CONTRAINDlCATJONS ALLEGRA iscontraindicated inpatients "nthknown hypersensitivity toany01 itsingredi ents. PRECAUTIONS Dru gIntera ct ion withErythromycinand Keloconazole Fexofenadinehy drochloride has been shown toexhibit minimal (ca. 5%) met abolism. However. co-administration offexolenadinehydr ochloride wi thketoconazoleand erythromycinledtoincreasedplasma levels01 lexolenadine hydrochloride. fexolenadinehy drochl ori dehadnoeffectonthe phar macokinet ics01 erythromycin andketoconazole. Inh'IOseparat estudies, lexolenadine hydrochloride120mg twice daily (h'IO timesthe recommended h'nce daily dose) was co-administer ed witherythromycin 500mgevery 8hoursorkei oconazole400 mgonce d a i~under steady-stateconditions tonormal, healthy volunteer s (n~24 , each study). No differ encesinadverse events or QT interval were observed whenpatientswereadminist eredfexofenadinehydrochloridealoneor incombination wi therythromycinor ketoconazole. Thelindings01thesestudies aresummarized inthe lollowinglable:
Elleels on stea dy-sl at elex ol enadinehydrochloride pharmacokinetics aller7 days 01 co-administrationwith lexolen adin ehyd rochloride 120mgevery 12hours (twotimes the recommended twice daily doseI innormal volunteers ( n~24 ) Concomitant C/74ltS$
AUCsSro. 12h}
Dr ug (Peakpl as ma concentration) (Extent 01systemicexposure) Erythromycin +82% +109%
(500mg every 8hrs) Ketoconazole +135% +164% (400 mg once daily) Thechanges inplasma levels wer ewithinthe range01 plasma levels achievedinadequate andwell-controlledcl inical trials. The mechanism ofthese interactions has been evaluat ed ininvitro, insitu, and invivoanimal models. Intraoperative findings or interest duri ng revision surgery were the presence or absence or cholesteatoma. the site o r persistent air-cell disease. and the presence or absence of a small meatus or a high facial ridge. The most common finding on revision surgery thought to be causally related to the previous surgical failure was an incomplete lowering of the facial ridge. which was seen in 30 of the 32 cases (94%) that had previously been treated by a canal-wall-down procedure (table 2) * SD = standard deviation ; PTA = pure-t one average . strated a reduction in the mean air-bone gap, but this improvement was not statistically significant.
Complications of revision surgery. Only two complications of revision surgery were noted. One patient developed a postoperative wound infection that required intravenous antibiotics; the infection subsequently resolved. Another patient deve loped a hematoma following tympanomastoid obliteration secondary to a rapid escalation of warfarin. The hematoma resolved after surgical debridement and placement of a muscle flap. There was no case of iatrogenic labyrinthine or facial nerve injury or iatrogenic postoperative sensorineural hearing loss.
Discussion
Revision surgery for chronic otitis media is clearly a more complicated and potentially risky unde rtaking than is primary surgery. In this series , there was a 16% incidence (8 of SO ears) of significant complications noted upon referral to our clinic. These complications included profound sensorineural hearing loss in two ears, two cases of facial paraly sis, and conditions related to the loss of dura l integrity. Cottrell and Pulec found similar complications in 740 patients who had undergone radical or modified radical mastoidectomy at Mayo Clinic. " Management of these issues at the time of revision surgery was enhanced by routine preoperative computed tomography (CT) . During our revision surgery, dura l dehiscence (36 % of cases) and facial nerve vulnerability as a result of 726 dehiscence (18%) were common, and thus they should be anticipated.
When looking at persistent unexenterated air cells in the mastoid system, 92 % of cases had persistent diseased air cells in the sinodural angle and 88% had persis tent disease involving tegmental air cells; subs tantially fewer patients had problematic air cells at the level of the mastoid tip or hypotympanum. It is unclear whether these findings alone or in comb ination with the addition al mechanical iss ues noted at the time of surgery were the causes of failure and persistent drainage. However, it is likely that the combined findings of a high facial ridge, a small meatus, and a failed drum graft were contributory.
In our study , 26 of the 32 cases (81 %) that had been previously treated by canal-wall -down surgery were found to involve an inadequate meatus. A high facial ridge was found to be a complicating factor in 30 of these 32 cases (94%). Also, 41 of the SO ears (82 %) had a failed drum graft. It is likely , then, that surgical failures were caused by the totality of these technical factors and not by merely one factor in and of itself. Others have noted this in the past and have indicated that these conditions are additional risk factors for a postoperative wet ear. 10 Although it is likely that these technical causes of failure are all contributory, it appears that the most common cause is a high facial ridge. It is likely that lowering the facial ridge reduces the incidence of these additional factors. For more information Circle 120 on Reader Service Card
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MEGERI AN, C OSENZA, MEYER Th e extent of surgical exe nteration during primary or rev ision surgery with regard to unin volved or unin fected air cells is controversial. Brandow advocated that areas of infected or diseased bone should be rem oved , although he wrote that "it is not necessary to look for and rem ove all noninfected cells."? In a review of causes of surgical failure in chronic ear surgery, Cheesman not ed that most otologis ts agreed that diseased cells should be removed , but he point ed out that there was a lack of agree me nt regarding the managem ent of the remaining health y cells." He wrote that it might not be necessary or practical to rem ove eve ry cell, especially if the drainage system remains unint errupted postope rati vely. However , during canal-wall-d own surge ry that includes the crea tion of a cavum minor and interruption of norm al mas toid drainage, Cheesman believed that it was necessary to "achieve tot al rem oval of all mastoid air cells except those not disturb ed by the cavity reconstruction." He stressed the need for attention to the sinodural-angle air cell s, the posteri or and lateral perilabyrinthine air cells, and the cell s in the mastoid tip.
In a large study by Jackson et al in 1996, the probl em cavity was mark ed by num erou s other mech anical issues." Although they are not listed here in order of their pre valen ce in revi sion cases, these issue s include problem s with a small meatu s, a high fac ial ridge, a dependent mastoid tip , tymp anic me mbrane perforation , granulation tissue, and retained cholesteatoma. In our series, all of these findings were signi ficant contributors. The occurrence of failed drum grafts that we noted on revision surge ry, however , was not limited to canal-w all-down surgeries; failed grafts co mplicated approximately 80% of both canal-wa ll-up and canal-wa ll-do wn proc edures.
It is possibl e that the constellation of techn ical problem s described in this and other reports occurs in a cascade dur ing surgery . For exa mple, failure to exentera te epitym panic tegment al air cells leaves disease in the attic region and possibly co ntributes to the eve ntual failure of the drum graft superiorly. Simil arly, failure to lower the facial ridge to the level of the fac ial nerve in the posteroinferior annul ar regio n might leave disease or trapp ed cells at the lev el of the hypotympanum, which can lead to granulation tissue and subsequent failure of the dru m graft inferiorly. It is likely that a failure to "s keletonize" the sinodural angle and unmask diseased tegm ental air cells lea ves behind diseased labyrinthine air cell s and obscures persistent chol esteatoma; these failures are often associated with the findin g of disease in the posterior epitympanum. Th erefore, it is possible that central to the many factors that complicate the chron icall y drainin g postoperat ive ear is the failure during initi al surge ry, and in some cases durin g revision surger y, to rem ove all air cell s, whether they are diseased or undi seased . In sum, the causes of failure noted in repor ts of rev isio n mastoid REVISION TYMPANOMASTOI D SURGERY Ultra surgery during thc 1970s and 1980s appear to be the same as they arc today.
It is interesting that the number of previous surgeries in this study did not appear to put thc patient at grea ter risk of failure. There was no appreciab le diffe rcnce in success rates between those who had undergone only one previous surgery and those who had underg one marc than one (93 and 95%. respectively).
Although thc primary goal of this type of proced ure is to create a clean. dry. and safe car. thc need to retain hearing is also significant." The hearing data in this report I reflec t short-term (mean: 26 mo) findings. Neve rtheless, the audiologic find ings were cncouraging. and they suggest that an improvement in hearing rather than mere preservation is a realistic expec tation.
Two weak nesses of our study arc that the size of the sample was relatively small and thc dura tion of follow-up was relatively short. Neverthele ss, neither oft hese limitations hindered our goal of highlighting and docume nting the outco mes d iffere nce s betwee n primary and seco ndary revision mastoid surger ies.
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